🟢 Kamada is trading 5.7% up today after confirming sufficient KedRAB inventory and manufacturing capacity

Kamada is trading 5.7% up at $8.65 after confirming sufficient KedRAB inventory and manufacturing capacity amid increased U.S. demand.

• The update followed a September 10, 2026 CDC advisory reporting increased rabies exposures and higher post-exposure treatment utilization.
• The advisory supports expectations for stronger demand for Kamada’s rabies immunoglobulin.
• Broader biotechnology strength and improving risk appetite are additional supportive factors.